Microdosing Mescaline for Health & Longevity - Quick Reference Sheet

Microdosing Mescaline for Health & Longevity

Created on 09/30/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Microdosing mescaline means repeatedly taking small, non-hallucinogenic amounts of a cactus-derived psychedelic, hoping for better mood, focus, sleep and brain health. Little evidence concerns mescaline microdoses; controlled studies of other psychedelics found few lasting benefits beyond expectation, a reading some consider premature. Open questions include unpredictable cactus strength, breaks from reality in vulnerable people, dangerous combinations with lithium and some antidepressants, and an unproven long-term heart-valve risk. Benefits remain unestablished. (Full Review)

Protocol

Dose range
10–40 mg mescaline
Occasionally 50 mg; one-tenth or less of a 300–500 mg full dose; higher exposure per milligram in lighter individuals favors starting at 10 mg
Every-third-day schedule
1 day on, 2 days off
Suits mescaline's long action and avoids accumulation; controlled microdosing trials use twice-weekly dosing
Time of day
Single morning dose
Splitting prolongs stimulation and makes perceptibility harder to judge
Time to effect
Reported subjective changes
1–2 weeks
Microdoser reports; no controlled data define a time course for lasting benefit
Acute onset
About 1 hour
After an oral dose; blood levels peak near 2 hours
Duration of acute effects
Roughly 3–6.5 hours
Subjective effects of 100 mg in trials; elimination essentially complete within 24–30 hours

Benefits

Contraindications
  • Personal history of schizophrenia, other psychotic disorder or bipolar I disorder, or a first-degree relative with either
  • Current lithium therapy
  • MAOI (monoamine oxidase inhibitor: phenelzine, tranylcypromine, moclobemide; Syrian rue, ayahuasca) therapy without a completed washout (at least 2 weeks for irreversible MAOIs)
  • Uncontrolled hypertension (resting blood pressure ≥140/90 mmHg despite treatment, or ≥160/100 mmHg at any time)
  • Known valvular heart disease (more than mild regurgitation or leaflet thickening on echocardiogram) or pulmonary arterial hypertension
  • Myocardial infarction (heart attack), stroke or unstable angina within the past 6 months
  • Seizure disorder
  • Pregnancy or breastfeeding
  • Severe kidney impairment (eGFR <30 mL/min/1.73 m²)
  • Adolescents under 18 years
Key Interactions
  • SSRIs and SNRIs (sertraline, escitalopram, venlafaxine): Caution
  • Tricyclic antidepressants (amitriptyline, nortriptyline): Caution
  • Antipsychotics and serotonin 2A blockers (quetiapine, risperidone, trazodone, ketanserin): Monitor
  • Stimulants and decongestants (amphetamine, methylphenidate; over-the-counter pseudoephedrine, phenylephrine): Caution
  • Over-the-counter serotonergic drugs and triptans (dextromethorphan cough syrups; sumatriptan): Caution
  • Serotonergic supplements (St. John's wort, 5-HTP, L-Tryptophan, SAMe): Caution
  • Blood-pressure-raising supplements (yohimbine, synephrine/bitter orange, high-dose caffeine, licorice): Caution
  • Other psychedelics and cannabis (psilocybin, LSD, cannabis): Caution
  • Alcohol: Monitor

Risk & Side Effects

  • High:
  • Medium:
  • Low: Nausea, headache and next-day discomfort; raised blood pressure, heart rate and body temperature; anxiety and unexpectedly strong effects; reduced cognitive control; psychosis or mania in susceptible individuals; persistent visual disturbances; craving and misuse
  • Speculative: Heart valve damage with long-term dosing; delayed sleep onset with late dosing

Monitoring

Marker Target Why
Blood pressure (seated) <120/80 mmHg Detects blood pressure rise
Resting heart rate 50–70 beats/min Detects stimulant effect
eGFR >90 mL/min/1.73 m² Kidney clearance of mescaline
ALT <25 U/L Screens liver health on co-medications
PHQ-9 score 0–4 Tracks depressive symptoms
GAD-7 score 0–4 Tracks anxiety
Echocardiogram No more than trace valve regurgitation; no leaflet thickening Detects valve changes
Sleep duration (wearable) 7–9 hours, within 30 minutes of own baseline Detects sleep disruption

Cadence: Baseline before the first dose; blood pressure 2 hours after each of the first three doses; questionnaires at 2, 4 and 8 weeks of each course; kidney and liver tests every 6–12 months; echocardiogram every 12 months once cumulative use exceeds 6 months

Qualitative Assessment

  • Mood stability on dosing versus off days
  • Energy and focus
  • Sleep quality on dosing nights
  • Anxiety or restlessness
  • Lingering visual changes
  • Social connection and meaning